Jon Napitupulu

Olema Pharmaceuticals announced preclinical data for OP-3136, a KAT6 inhibitor, showing anti-tumor activity in ovarian, prostate, and non-small cell...

Harbinger Health presented new research at the American Association for Cancer Research (AACR) Annual Meeting showcasing advancements in their...

Zenflow, Inc. released three-year data from its ZEST pilot studies, demonstrating sustained positive outcomes for patients using the Zenflow...

Janssen-Cilag International NV announced promising interim results from the Phase 2b SunRISe-1 study (Cohort 4) of TAR-200, a gemcitabine-releasing...

Protara Therapeutics announced updated Phase 2 trial results for TARA-002, a cell-based therapy for Non-Muscle Invasive Bladder Cancer (NMIBC)....

Stablepharma Ltd. has initiated a Phase 1 clinical trial for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria...

Foghorn Therapeutics announced preclinical data for several potential first-in-class cancer medicines, including FHD-909, a SMARCA2 inhibitor, and its selective...

Tenaya Therapeutics announced interim data from its RIDGE natural history study of adults with arrhythmogenic right ventricular cardiomyopathy (ARVC)...

Verana Health launched Qdata® Cataracts, a comprehensive dataset on cataract surgery outcomes derived from over 9 million de-identified patients...

Inmagene Biopharmaceuticals announced positive topline results from a Phase 2a trial of IMG-007, a non-depleting anti-OX40 monoclonal antibody, in...